Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Carbapenem antibiotic
Original Date: 
August 2005
Revised Date: 
October 2021
  • Treatment of infections caused by susceptible bacteria.

** Prescribing is restricted to Infectious Disease **

Reconstitution and Stability: 




500 mg

10 mL

50 mg/mL

1,000 mg

20 mL

50 mg/mL

  • Shake to dissolve and let stand until clear.
  • Reconstituted solutions stable 3 hours room temperature, 24 hours refrigerated.
  • Solution ranges in color from colorless to pale yellow.
  • Solutions Compatible: D5W, 0.9%NS, D5NS, ringer's solution, ringer's lactate
  • Additives/Above Cassette Compatible: no information
  • Y-site Compatible: aminophylline, dexamethasone, digoxin, diphenhydramine, fluconazole,​ furosemide, metoclopramide, morphine, norepinephrine, potassium (up to 40 mmol/L) vancomycin, TPN (amino acids/dextrose)

Incompatible: acyclovir, amphotericin B, diazepam, doxycycline, metronidazole, ondansetron, zidovudine.




(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct


IV Intermittent Infusion

Usual dilution: 20 mg/mL
Infusion time: 30 minutes

IV Continuous Infusion NO



(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric: (>3 months)
- Infection: 60 mg/kg/day IV ÷ Q  6 - 8 hours (Maximum: 3 g/day)

- Meningitis/Cystic Fibrosis patients with LRTI:  120 mg/kg/day IV ÷ Q 6 - 8 hours  (Maximum: 6 g/day)

- Infection:   1.5-3 g/day IV ÷ Q 6 - 8 hours

- Meningitis: 6 g/day IV ÷ Q 8 hours


  • CrCl 26-50 mL/minute: full dose Q 12 hours
  • CrCl 10-25 mL/minute: ½ dose Q 12 hours
  • CrCl <10 mL/minute: ½ dose Q 24 hours
  • Meropenem is removed by hemodialysis; therefore, administer dose at completion of hemodialysis procedure
Potential hazards of parenteral administration: 
  • Thrombophlebitis, phlebitis, inflammation at injection site
  • Headache, diarrhea, pseudomembranous colitis, nausea, vomiting
  • Transient increase in liver enzymes, liver function tests and bilirubin
  • Elevated BUN and serum creatinine
  • Rash, pruritus, urticaria
  • Increases in platelets occur more frequently in pediatric patients
  • Seizures (rare)
  • Use with caution in patients with a history of seizures, CNS disease, CNS infection,
  • May exhibit cross-allergy with penicillins or cephalosporins
  • Monitor CBC with differential, serum creatinine and BUN, periodic hepatic function tests
  • 1 gram of meropenem provides 90.2 mg (or 3.92 mmol) of sodium

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.